Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience

Gisondi, Paolo; Piaserico, Stefano; Naldi, Luigi; Dapavo, Paolo; Conti, Andrea; Malagoli, Piergiorgio; Marzano, Angelo Valerio; Bardazzi, Federico; Gasperini, Massimo; Cazzaniga, Simone; Costanzo, Antonio; Sacchelli, Lidia; Pezzolo, Elena; Messina, Francesco; Lasagni, Claudia; Bigi, Laura; Cattaneo, Angelo; Carrera, Carlo Giovanni; Arancio, Luisa; Ribero, Simone; Rozzo, Giulia; Damiani, Giovanni; Facheris, Paola

doi:10.1016/j.jaci.2020.10.032

Cited by 54 publications

(56 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, there was no significant increased risk of hospitalization associated with COVID-related interstitial pneumonia. These observations have been confirmed in other studies [ 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ]. PsoProtect (Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of Covid-19 infecTion) is an international web-based registry (www.psoprotect.org) for healthcare providers to report outcomes of COVID-19 in individuals with psoriasis [ 70 ].…”

Section: Biologics For Psoriasissupporting

confidence: 88%

Biologics for Psoriasis during the COVID-19 Pandemic

Komine

Ohtsuki

2021

JCM

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.

show abstract

Section: Biologics For Psoriasissupporting

confidence: 88%

Biologics for Psoriasis during the COVID-19 Pandemic

Komine

Ohtsuki

2021

JCM

View full text Add to dashboard Cite

show abstract

“…Moreover, Cho et al concluded in their epidemiological study that biologics for dermatological conditions did not seem to influence the susceptibility or mortality related to COVID-19, suggesting that biologics might be continuously used during the COVID-19 pandemic (63). As proof of this, Gisondi et al found no negative impact of biologics on COVID-19 outcome in patients with psoriasis and did not advise discontinuation of biologic treatment of psoriasis to reduce the risk of SARS-CoV-2 infection (67). Data on a small cohort of patients with moderate-to-severe atopic dermatitis treated with dupilumab, a monoclonal antibody inhibiting the shared receptor component for IL-4 and IL-13, also suggest no increased risk for COVID-19 in this subset (55).…”

Section: Cutaneous Diseasesmentioning

confidence: 99%

How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group

et al. 2021

View full text Add to dashboard Cite

Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.

show abstract

“…Our patient was on Methotrexate (immune‐suppressant) for his psoriasis, with the last dose taken two weeks before hospitalization. A multi‐center study in Italy found that the incidence rate of death due to COVID‐19 disease was lower in patients with psoriasis (under biological therapy) than in general population, suggesting no need of discontinuing ongoing therapy 16 . Additionally, during hospitalization, the patient was treated with higher than normal dose of prophylactic anticoagulant (Enoxaparin 80mg q24h) 17 .…”

Section: Discussionmentioning

confidence: 99%